Preview Mode Links will not work in preview mode

Coronavirus (COVID-19) Q&A

Sep 23, 2020

Hydroxychloroquine and convalescent plasma approvals by the FDA under Emergency Use Authorization (EUA) protocols have raised concerns the agency is under withering political pressure to fast-track a COVID-19 vaccine before it is proven safe and effective. Joshua Sharfstein, MD, Johns Hopkins Bloomberg School of Public Health, and JAMA Associate Editor Preeti Malani, MD, University of Michigan, discuss implications for public health and policy responses to ensure vaccine safety. Recorded September 18, 2020.

Related Article:

Reassuring the Public and Clinical Community About the Scientific Review and Approval of a COVID-19 Vaccine